← Leaderboards
Shane Hegarty
Axonis Therapeutics, Inc.
$1,095,744
Attributed
$1,257,244
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $634.5K · FY2022–24$1M$750K$500K$250K$0
'22
'23
'24
Funding mix
By agency
NIH$1,257,244 · 4
By mechanism
R43$1,257,244 · 4
Top collaborators
- Shilpa Dattatray Kadam1 shared
Most similar at Axonis Therapeutics, Inc.
Same institution · by research overlap
- Joanna Stanicka$2,531,313
Others in their field
Other Rising Stars on “Neurons”
- Sabrina Paganoni · Massachusetts General Hospital$15,344,018
- Suma Babu · Massachusetts General Hospital$15,344,018
- Thomas K Karikari · Wake Forest University Health Sciences$12,972,426
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Eric Anderson · Columbia University Health Sciences$11,474,975
- Jinsy Andrews · Columbia University Health Sciences$11,474,975
Research focus
NeuronsChronicIn VivoSmall Business Innovation Research GrantPropertyRodentRattusDown-RegulationPersonsPathologyPharmacodynamic BiomarkerQuality Of LifeEquilibriumGene TherapyMeasurementChloridesLeadMembraneAcutePainDosePathologicPharmaceutical PreparationsSmall Molecule
Grant awards (4)
Development of Oral KCC2 Potentiator AXN-027 as a Novel Anti-Epileptic Drug for Mesial Temporal Lobe Epilepsy$323,001
R43 · FY2024 · NS
Development of oral KCC2 enhancer drug for treatment of painful diabetic neuropathy$299,756
R43 · FY2023 · DK · contact PI
Development of Neuromodulating AAV-KCC2 Gene Therapy to Treat Paralysis, Spasticity and Neuropathic Pain after Spinal Cord Injury$335,668
R43 · FY2022 · NS · contact PI
Development of AAV-AXN-007 gene therapy to treat glaucoma.$298,819
R43 · FY2022 · EY · contact PI